Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. - Wikidata - wikimedia - TriplyDB

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.

http://www.wikidata.org/entity/Q34253139

about

A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial.Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.Early factors in successful anti-HIV treatment.Lung cancer in HIV Infection.A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study.Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics.Atazanavir for the treatment of human immunodeficiency virus infection.Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients.Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.Amide hydrogen exchange in HIV-1 subtype B and C proteases--insights into reduced drug susceptibility and dimer stability.Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir.Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.Coadministration of milk thistle and indinavir in healthy subjects.

P2860

Q33559216-E433CC8D-1D59-4023-8F66-24C1417EE73A Q33681426-A695CC13-614F-4568-AAAC-79317F433576 Q33769950-62CCD174-B67D-4B05-8231-1B7379D5F665 Q34114808-593F799E-2501-43F3-BF0C-A59A8809B3EF Q34720072-7E10CDFD-C7C3-4D76-83D0-E544A60EB343 Q35207282-26924799-1DF3-4B22-9285-6A00469B5432 Q35667193-730D6827-9C56-4706-9265-12AEE91FECEE Q35894312-9C2BEDBC-EC32-487C-93F7-70A106483BB0 Q35917140-70D021C4-53C1-4D7F-940F-AB9A380C4A60 Q35976835-1F04D937-B01B-4950-AB1F-1A9A1CC5858C Q37489345-994F28D4-4F6F-4279-99DA-74462DD58C2D Q38954109-F87EE1F5-A2A0-4A41-85A4-86EA31E5BFFF Q40131713-09A649FE-117A-4D6F-BA1B-2EBA290D11C3 Q41269323-48619F4E-462C-4534-A657-E2752C22E24F Q42184665-5054B518-69CB-4FDF-B7B5-AC03E8221A13 Q43039208-8F14FA19-43AD-444A-875D-A76B772CCAD6 Q43204477-1DF0A379-CD2B-48AE-A69D-6CDB359FFDBE Q44528630-6362DBED-648E-4066-AB48-3EB75273401C

P2860

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.

http://www.wikidata.org/entity/Q34253139

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Virtual inhibitory quotient pr ...... patients with ongoing viremia.

@ast

Virtual inhibitory quotient pr ...... patients with ongoing viremia.

@en

Virtual inhibitory quotient pr ...... patients with ongoing viremia.

@nl

type

label

Virtual inhibitory quotient pr ...... patients with ongoing viremia.

@ast

Virtual inhibitory quotient pr ...... patients with ongoing viremia.

@en

Virtual inhibitory quotient pr ...... patients with ongoing viremia.

@nl

prefLabel

Virtual inhibitory quotient pr ...... patients with ongoing viremia.

@ast

Virtual inhibitory quotient pr ...... patients with ongoing viremia.

@en

Virtual inhibitory quotient pr ...... patients with ongoing viremia.

@nl

P1433

Q34253139-B71BC48D-C96D-4A7B-99DC-AFC2687C0334

P1476

Q34253139-3F4661B2-CAC9-4F2B-9B39-4CA02F3959C8

P2093

Q34253139-23A907FF-146F-4D4B-A5CA-106A461136F3

Q34253139-3259F91D-02C3-4D26-AA23-083AEA237A4B

Q34253139-6C0B804F-314A-4971-8F6F-3F8D8207EC28

Q34253139-70064597-84E5-43E8-8253-3527FE95049E

Q34253139-72B2AF73-ED04-4216-9CF7-0FAB50B81E8E

Q34253139-771DC7F1-A0F9-417D-88A1-480D9024DB0D

Q34253139-9089AED4-FAA5-4C3F-BACF-6E923CC2436C

Q34253139-9AA0471B-DA44-492C-A865-E24258093920

Q34253139-A53D72DE-8DEB-47E9-8E17-017952B26172

Q34253139-A6EF2C8C-44E7-400A-AECE-6643C86ADFC3

P2860

Q34253139-12551120-F7A9-4864-B469-552A4478C4C1

Q34253139-14799B26-57F5-4DE2-89C5-D570C0AE41DF

Q34253139-4BC83786-B2C2-4235-BC8E-500401D01065

Q34253139-5532BE0D-F17B-4049-BB40-C8A8D2B61D35

Q34253139-64340B9A-6AB0-493A-9943-DE7FF9224C6D

Q34253139-6B006046-CED6-4555-B09E-1E1209075D3C

Q34253139-6DD5D3D7-06B4-4F8E-A40D-9A6CAF49F2F8

Q34253139-72401117-FDAC-4E6F-8B88-6D66FEBDDBB6

Q34253139-766EF937-8F64-4E91-B6DD-6396B8EC95B6

Q34253139-81ED38C6-CF07-4EC2-95C4-D24D42DC9B69

P304

Q34253139-D46AD27A-85C4-4975-B1B8-53AEB818EC78

P31

Q34253139-5A48485B-DF45-481D-A427-E1DCB76AA7A6

P356

Q34253139-E41BA9B0-B081-44D2-9437-BC8B745D9A9C

P407

Q34253139-BD86DC0A-B521-4E26-8891-44F514DA704F

P433

Q34253139-510F736E-A440-4015-8A3F-0D517940E2F9

P478

Q34253139-EDCCF0E9-2039-431D-9767-87BC25B79935

P50

Q34253139-347EB151-4880-433F-AA15-519E8BB55AF0

P577

Q34253139-62DE1354-18FB-431E-9BA0-191AA4FEB605

P698

Q34253139-0E55578B-B761-4FD8-BD11-F4B8C8B89975

P932

Q34253139-14D63EFC-CC84-41F1-A909-9644863B9BB2

P356

AAC.46.12.3907-3916.2002

P1433

Antimicrobial Agents and Chemotherapy

P1476

Virtual inhibitory quotient pr ...... patients with ongoing viremia.

@en

P2093

Andrew Zolopa

http://www.w3.org/2001/XMLSchema#string

Ann Hsu

http://www.w3.org/2001/XMLSchema#string

Cheryl Renz

http://www.w3.org/2001/XMLSchema#string

Dale J Kempf

http://www.w3.org/2001/XMLSchema#string

Elizabeth Race

http://www.w3.org/2001/XMLSchema#string

Eugene Sun

http://www.w3.org/2001/XMLSchema#string

Joel Gallant

http://www.w3.org/2001/XMLSchema#string

Nancy Shulman

http://www.w3.org/2001/XMLSchema#string

Ping Jiang

http://www.w3.org/2001/XMLSchema#string

Richard Rode

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers

Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits.

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.

A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.

Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment.

P304

3907-3916

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.46.12.3907-3916.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12435695

http://www.w3.org/2001/XMLSchema#string

P932

132776

http://www.w3.org/2001/XMLSchema#string